You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

26 search results for: CRSwNP

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in <b>CRSwNP</b>

expert video

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

30 min

Rhinology

Prof. Joaquim Mullol presents on the proposed mechanisms of smell loss and nasal congestion in CRSwNP.

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in <b>CRSwNP</b>

expert video

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

7 min

Rhinology

Prof. Joaquim Mullol describes the burdens of smell loss and nasal congestion for patients with uncontrolled and/or severe CRSwNP.

expert video

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

2 min

Rhinology

This video clip from the EAACI 2024 symposium discusses whether patients with CRSwNP should undergo a surgery.

Importance of Endotyping in <b>CRSwNP</b>

expert video

Importance of Endotyping in CRSwNP

2 min

Rhinology

Prof. Wytske Fokkens discusses the role of endotyping in the management of CRSwNP.

IRS-ISIAN 2024 | Guideline Definitions of Control in <b>CRSwNP</b>

expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

5 min

Rhinology

Prof. Peter Hellings explores the concept of disease control in CRSwNP.

The Pathophysiology of Type 2 Inflammation in <b>CRSwNP</b>

interactivity

The Pathophysiology of Type 2 Inflammation in CRSwNP

5 min

Rhinology

Learn how type 2 inflammation underlies the pathophysiology of CRSwNP

expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP

Partnering With Patients for Clinical Decision-Making in <b>CRSwNP</b>

expert video

Partnering With Patients for Clinical Decision-Making in CRSwNP

2 min

Rhinology

Profs. Wytske Fokkens and Joaquim Mullol investigate the importance of partnering with patients with CRSwNP in clinical decision-making.

Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

15 min

Rhinology

Profs. Wytske Fokkens and Joaquim Mullol discuss the clinical significance of the loss of smell in patients with CRSwNP.

Podcast

ADVENT On Air | Remission in CRSwNP

19 min

Rhinology

Prof. Peter Hellings and Dr. Stella Lee discuss the concept of remission for patients with chronic rhinosinusitis with nasal polyps.

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent <b>CRSwNP</b>

expert video

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

9 min

Rhinology

Prof. Joaquim Mullol reports on biologic improvements in sense of smell and nasal congestion in patients with and without a history of endoscopic sinus surgery.

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, <b>CRSwNP</b>, and EoE

Infographic

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE

5 min

Type 2 Inflammation

Discover how barrier dysfunction, neuroimmune dysregulation, and type 2 inflammation contribute to the pathophysiology of various diseases

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FranceChange country/region